Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 9/20 | 0.54 |
| ▸ | F9 | P00740 | 4/20 | 0.54 |
| ▸ | F11 | P03951 | 3/20 | 0.54 |
| ▸ | F7 | P08709 | 4/20 | 0.48 |
| ▸ | F2 | P00734 | 6/20 | 0.48 |
| ▸ | PLAU | P00749 | 6/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.48 |
| ▸ | PLG | P00747 | 5/20 | 0.48 |
| ▸ | PLAT | P00750 | 4/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10172714 | 0.91 | F10 (0.51) | F10F9F11F7F2 | |
| SCHEMBL7975521 | 0.88 | F10 (0.63) | F10F9F11F7F2 | |
| SCHEMBL10140008 | 0.87 | F10 (0.57) | F10F9F11F7F2 | |
| SCHEMBL7961686 | 0.85 | CHEK2 (0.58) | F10F9F11F7CHEK2 | |
| SCHEMBL7969986 | 0.85 | F10 (0.58) | F10F9F11F7F2 | |
| SCHEMBL10139996 | 0.85 | F10 (0.54) | F10F9F11F7F2 | |
| SCHEMBL7966275 | 0.84 | F10 (0.51) | F10F9F11F7F2 | |
| SCHEMBL16258934 | 0.83 | F10 (0.54) | F10F9F11F7F2 | |
| SCHEMBL10139901 | 0.83 | F10 (0.54) | F10F9F11F7F2 | |
| SCHEMBL7960525 | 0.83 | F10 (0.56) | F10F9F11F7F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805939-B1 | Heterocyclic compounds as factor IXA inhibitors. | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2805939-A1 | Heterocyclic compounds as factor IXA inhibitors. | Merck Sharp & Dohme Corp. (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | F9, F12, F8 | F10 11/4885F9 1/4885F11 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.